Table 5: GRADE evidence profile for oral amantadine versus no antiviral therapy

Quality assessment							Summary of Findings				
Participants (studies) Follow up *to 30 days*	**Risk of bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Publication bias**	**Overall quality of evidence**	**Study event rates (%)**		**Relative effect** (95% CI)	**Anticipated absolute effects**	
							With no antiviral treatment	**With amantadine**		**Risk with no antiviral treatment**	**Absolute effect with amantadine** (95% CI)
Mortality											
139 (1 study)	serious[1]	no serious inconsistency	no serious indirectness	serious[2]	undetected[3]	⊕⊖⊖⊖ **VERY LOW**[1,2,3] due to risk of bias, imprecision	8/62 (12.9%)	0/77 (0%)	**OR 0.04** (0 to 0.73)	**129 deaths per 1000**	**123 fewer deaths per 1000** (from 31 to 129 fewer)
- not measured											
Duration of hospitalisation (measured with: days; Better indicated by lower values)											
78 (1 study)	serious[1]	no serious inconsistency	no serious indirectness	serious[2]	undetected	⊕⊖⊖⊖ **VERY LOW**[1,2] due to risk of bias, imprecision	27	51	-	-	The mean duration of hospitalisation was **1.01 fewer days** (0.27 to 1.75 fewer)
Duration of signs and symptoms (measured with: hours from onset of symptoms; Better indicated by lower values)											
1508 (3 studies)	serious[4]	serious[5]	no serious indirectness	no serious imprecision	undetected[3]	⊕⊖⊖⊖ **VERY LOW**[3,4,5] due to risk of bias, inconsistency	-	1508	-	-	-[6]
Complications - Pneumonia											
139 (1 study)	serious[1]	no serious inconsistency	no serious indirectness	serious[2]	undetected[3]	⊕⊖⊖⊖ **VERY LOW**[1,2,3] due to risk of bias, imprecision	24/62 (38.7%)	25/77 (32.5%)	**OR 0.76** (0.38 to 1.53)	**387 pneumonia per 1000**	**63 fewer pneumonia per 1000** (from 194 fewer to 104 more)
Minor adverse events											
832 (3 studies)	serious[1,4]	no serious inconsistency	no serious indirectness	no serious imprecision	undetected[3]	⊕⊖⊖⊖ **VERY LOW**[1,3] due to risk of bias	-	6/832 (0.7%) Pooled risk (95% CI) 0% (0 to 1)	-	-	-
Hospitalisation, ICU admission/mechanical ventilation/respiratory failure, time to return to normal activity, viral shedding - not measured											

[1] Studies not adjusted for potential confounding factors.
[2] Few events and participants.
[3] Although we did not downgrade, publication bias cannot be excluded.

[4] Studies did not have comparison groups.
[5] High heterogeneity among studies.
[6] The mean time to alleviation of symptoms for people who had amantadine was 64 hours (63 to 65 hours). There is no comparison group.